WinstonWınston
NewCardio logo

NewCardio

NWCI
Medical - Devices · Healthcare
Price
$0.00
+0.00 (+0.00%)
Market Cap
$3,315
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+239.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 8.4M (2006) → 28.6M (2010)

NewCardio, Inc. is a small medical technology company focused on heart health. It develops software tools that help doctors read and interpret electrocardiograms, which are the tests that measure electrical activity in the heart. Its main customers are hospitals, clinics, and healthcare providers who need more accurate ways to detect heart problems.

The company earns revenue by licensing its cardiac analysis software to medical institutions. NewCardio operates primarily in the United States and is a very small company, with a market cap that rounds to essentially zero, meaning it has little financial scale compared to larger medical device firms. Its operating margin is deeply negative, which means it is spending far more than it earns — a serious concern for a company this size. The key risk is straightforward: NewCardio must find a way to grow revenue and reduce losses before it runs out of resources, as tiny healthcare software companies face intense competition from much larger, well-funded rivals.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-90.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+12.5% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$4M/ year

Rising (+18% vs prior year)

>1,000% of revenue

77.4x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

24.1%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$13,064 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

NewCardio is putting 1393% of revenue into R&D and that number is rising. That's 77.4x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-177.9%
Thin — -177.9% gross margin
Operating Margin
-15764.4%
Losing money on operations — -15764.4%
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+40.9%
Fast-growing sales (40.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-1110.2%
Burning cash (-1110.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial